CLINICAL PAIN NEUROSCIENTIST TALKS ABOUT HOW THE BRAIN PROCESSES PAIN INFORMATION Trial: affects on pain and activity levels, by educating knee osteoarthritis participants in individualised exercise programs
With
Tasha Stanton,
Associate Professor of Clinical Pain Neuroscience
Group, Leader Persistent Pain Research Group (Lifelong Health)
SAHMRI (South Australian Health and Medical Research Institute) &
co-Director of IMPACT in Health, University of South Australia
SEGMENT
Filmed in Adelaide | March 2026
The Persistent Pain Research Group’s vision is to work hand-in-hand with consumers to undertake impactful research that helps better understand and treat persistent pain.
Their studies span discovery to implementation science to determine key contributors to the development and maintenance of persistent pain and to use this information to create novel brain-based interventions.
They hold expertise in developing new technologies, such as virtual and mediated reality, and translating these technologies to the clinical environment, using innovative co-design methods.
The Persistent Pain Research Group studies a variety of painful conditions, with specific focus on:
- Osteoarthritis
- Spinal pain (neck and back)
- Complex regional pain syndrome
- Phantom limb pain after amputation
Persistent pain affects one in five Australians and costs the nation an estimated $73 billion per year in health system costs, lost productivity and other financial costs.
Persistent pain also has debilitating personal costs – negatively impacting quality of life and the ability to engage in meaningful work and life activities.
Despite the enormity of this problem, very few effective treatments exist with most showing only small to moderate improvements. New treatments are desperately needed. The group believes the best way to create impactful change is to work with people with lived experience of persistent pain to devise solutions with them, not for them.
Source: SAHMRI webpage Persistent Pain Research Group
-
The role of genomic screening in transforming public health
Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.
-
Artificial Intelligence (AI) & data skilling clinicians
In this first release, world renowned AI and medical data science experts Dr Anthony Chang and Professor Enrico Coiera spoke to Australian Health Journal reporter Anne Dao at AIMed 2019 Sydney. The conference aimed at clinicians and non-clinicians discussed current clinical applications of Artificial Intelligence in medical imaging, decision support, use of predictive healthcare and machine learning.
-
Reporting on Australian childhood visual impairment: the first 10 years
The Australian Childhood Vision Impairment Register (ACVIR), the first of its kind in Australia, captures uniquely Australian data which is used to improve services for children with vision impairment. The data is also available to researchers who work in the area of eye disease and disorders of vision.
